Clinical Trial Update: Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating topotecan with the ATR inhibitor M6620 (VX-970) in small cell lung cancer and extrapulmonary small cell neuroendocrine carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Small Cell Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• M6620 (berzosertib)
• Topotecan (topotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-13